Atossa Genetics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 97.76. In total, the insiders bought 29 257 663 and sold 3 379 162 ATOS shares in the last 100 trades.

Insider Power

(Last 100 transactions)
97.76
Buy 29 257 663 Shares
Sell 3 379 162 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 27, 2024 Stock Option (right to buy) Buy Finn Jonathan 125 000
Jun 27, 2024 Stock Option (right to buy) Buy Remmel H. Lawrence 125 000
Jun 27, 2024 Stock Option (right to buy) Buy Steinhart Richard I 125 000
Jun 27, 2024 Stock Option (right to buy) Buy Chen Shu-chih 125 000
Jun 27, 2024 Stock Option (right to buy) Buy Rees Heather 577 700
Jun 27, 2024 Stock Option (right to buy) Buy Quay Steven C 1 795 100
Jun 27, 2024 Stock Option (right to buy) Buy Galli Stephen J 125 000
Jun 27, 2024 Stock Option (right to buy) Buy Cigler Tessa 125 000
Apr 10, 2024 Common Stock Buy Finn Jonathan 25 000
Mar 09, 2024 Stock Option (right to buy) Buy Cigler Tessa 20 834
Mar 09, 2024 Buy Cigler Tessa 0
Nov 15, 2023 Common Stock Sell Weaver Gregory L 50 000
Nov 15, 2023 Stock Option (right to buy) Buy Finn Jonathan 62 500
Nov 15, 2023 Stock Option (right to buy) Buy Finn Jonathan 62 500
Nov 08, 2023 Buy Finn Jonathan 0
Oct 06, 2023 Stock Option (Right to Buy) Buy Rees Heather 32 500
Oct 06, 2023 Stock Option (Right to Buy) Buy Rees Heather 100 000
Oct 06, 2023 Stock Option (Right to Buy) Buy Rees Heather 129 700
Oct 06, 2023 Stock Option (Right to Buy) Buy Rees Heather 150 000
Oct 06, 2023 Stock Option (Right to Buy) Buy Rees Heather 226 000
Jun 20, 2023 Common Stock Buy Weaver Gregory L 50 000
Jun 01, 2023 Stock Option (right to buy) Buy Weaver Gregory L 2 600 000
May 04, 2023 Stock Option (right to buy) Buy Weaver Gregory L 125 000
May 04, 2023 Stock Option (right to buy) Buy Remmel H. Lawrence 125 000
May 04, 2023 Stock Option (right to buy) Buy Steinhart Richard I 125 000
Click to get the best stock tips daily for free!

About Atossa Genetics Inc.

Atossa Genetics Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patien... ATOS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT